Mer­ck KGaA ex­pands its deal with Pfiz­er/BioN­Tech with an eye on a key vac­cine man­u­fac­tur­ing bot­tle­neck

As Pfiz­er and BioN­Tech’s vac­cine de­liv­ery runs be­hind sched­ule in the EU, Mer­ck KGaA is aim­ing to boost pro­duc­tion by ac­cel­er­at­ing its sup­ply of cus­tom lipids to BioN­Tech.

The Darm­stadt, Ger­many-based biotech has promised to ex­pand its pro­duc­tion of lipids, which are crit­i­cal in get­ting the mR­NA tech­nol­o­gy in­to the body. Com­pli­cat­ing mat­ters fur­ther is that on­ly a se­lect few man­u­fac­tur­ers are cur­rent­ly equipped to man­u­fac­ture the lipids in stan­dards con­sis­tent enough for vac­cine pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER